Kelsee, I guess the Endocyte article indicated to me that there may actually be some hope in "whatever expectation" Don has established, but of course I don't have the skills to understand why Endocyte succeeded and then compare their conditions to the current state of zen3694.

From the Market Watch article BDAZ linked....But it was a deal that Endocyte made a few months later that now looks like straw spun into gold: A $12 million upfront licensing agreement for an investigational therapy, Lu-PSMA-617, that uses radiotherapy to target cancer cells. The drug is intended for a hard-to-treat type of cancer, metastatic castration-resistant prostate cancer.

Endocyte called the deal “transformational” in 2017—and it was. On Thursday, Swiss pharmaceutical giant Novartis International AG NVS, +1.25%  said it planned to buy the biotech for a total value of $2.1 billion, sending shares zooming more than 50%.

What strikes me is what I underlined..."investigational" drug. Perhaps a BP could actually be watching the zen3694 research. 

But as I posted previously, while Don seemed very enthused at the AGMs my sense is that he has not got the business side buttoned down.

A back of the napkin calculation based on the outstanding Zenith shares would put the endocyte deal at $12USD/share.

I'm still hoping.

Toinv